Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease
Molecules · 19.11.2025 · 30 (22) · 4456
DOI: 10.3390/molecules30224456 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 19.11.2025. Verfasst von Keanie Ward und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, Banyo, QLD 4014, Australia. Hauptthemen laut MEDLINE: Seaweed, Alzheimer Disease, Neuroprotective Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Cognitive decline associated with healthy ageing and pathological conditions is driven by multifactorial processes, including oxidative stress, mitochondrial dysfunction and chronic neuroinflammation. Alzheimer’s Disease (AD), a progressive neurodegenerative disorder affecting cognition and behaviour, is the leading cause of dementia worldwide. Current pharmacological interventions provide modest and transient benefits, targeting limited molecular pathways with safety and cost concerns, underscoring the need for safe, accessible and multi-targeted strategies. This review explores new avenues of therapy with a focus on bioactive compounds derived from brown, red and green seaweeds and their potential to modulate key mechanisms underlying AD. Preclinical and emerging clinical studies demonstrate that phlorotannins, fucoidans, fucoxanthin, lutein, zeaxanthin, ulvan, and astaxanthin exert antioxidant, anti-inflammatory, cholinergic-modulating and neuroprotective effects. Supplementation with seaweed-derived bioactive compounds has been shown to exert molecular and cellular effects that lead to reduced amyloid burden, preservation of synaptic integrity, and enhanced cognitive performance. Collectively, seaweed-derived compounds represent promising candidates for multi-target therapeutic strategies in cognitive decline prevention in the context of AD and healthy brain ageing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, Banyo, QLD 4014, Australia.
- Healthy Brain and Mind Research Centre, Australian Catholic University, Fitzroy, VIC 3065, Australia.
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD 4059, Australia.
- Venus Shell Systems Pty Ltd., Huskisson, NSW 2540, Australia.
- School of Medical, Indigenous and Health Science, University of Wollongong, Wollongong, NSW 2522, Australia.
- Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.
ORCID-Profile: Michael H Cole, Lyn R Griffiths, Heidi G Sutherland, Pia Winberg, Barbara J Meyer, Francesca Fernandez
Zitieren
APA
Ward, K., Cole, M. H., Griffiths, L. R., Sutherland, H. G., Winberg, P., Meyer, B. J., & Fernandez, F. (2025). Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease. Molecules, 30(22), 4456. https://doi.org/10.3390/molecules30224456
Vancouver
Ward K, Cole MH, Griffiths LR, Sutherland HG, Winberg P, Meyer BJ, et al. Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease. Molecules. 2025;30(22):4456. doi:10.3390/molecules30224456
BibTeX
@article{Ward2025,
author = {Ward, Keanie and Cole, Michael H and Griffiths, Lyn R and Sutherland, Heidi G and Winberg, Pia and Meyer, Barbara J and Fernandez, Francesca},
title = {Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease},
journal = {Molecules},
year = {2025},
volume = {30},
number = {22},
pages = {4456},
doi = {10.3390/molecules30224456}
}
EUVIMED